What is Onc.AI?
Onc.AI operates as a specialized technology enterprise dedicated to the advancement of precision oncology through the application of artificial intelligence and machine learning. By synthesizing vast, real-world datasets with sophisticated computer vision and medical imaging capabilities, the company provides a comprehensive suite of predictive tools designed to assist oncologists in navigating complex treatment landscapes. The organization is composed of a multidisciplinary team of scientists, medical experts, and software engineers who are focused on building a scalable pipeline of products that integrate seamlessly into existing clinical workflows. Their market position is defined by a commitment to evidence-based innovation, ensuring that their AI-driven solutions not only meet the rigorous demands of modern medical practice but also drive significant improvements in the efficacy of cancer care delivery.
How much funding has Onc.AI raised?
Onc.AI has raised a total of $31M across 2 funding rounds:
Unspecified
$6M
Series A
$25M
Unspecified (2020): $6M with participation from Digitalis Ventures, The Blue Venture Fund, Accomplice, and KdT Ventures
Series A (2023): $25M led by The Blue Venture Fund, Digitalis Ventures, Action Potential Venture Capital, MassMutual, and Accomplice
Key Investors in Onc.AI
The Blue Venture Fund
A strategic partnership among Blue Cross Blue Shield companies that focuses on advancing healthcare through investments in technology, services, and clinical sciences to improve patient outcomes.
Digitalis Ventures
A multidisciplinary venture firm that engineers solutions to unmet health needs by leveraging deep technical and domain expertise to scale enduring biotechnology and technology-enabled enterprises.
Action Potential Venture Capital
A specialized medical technology venture capital firm established by GSK, focusing on the development of bioelectronic medicines and innovative therapies that target the nervous system.
What's next for Onc.AI?
Looking ahead, the strategic deployment of the $25M capital will likely focus on the expansion of the company's clinical product pipeline and the scaling of its enterprise software infrastructure. As Onc.AI moves deeper into the commercialization phase, the focus will shift toward strengthening partnerships with healthcare providers and expanding the reach of its multimodal predictive models. The company is well-positioned to capitalize on the growing demand for digital health solutions that offer tangible improvements in diagnostic accuracy and treatment planning. By maintaining its focus on physician-centric design and leveraging its deep expertise in predictive analytics, Onc.AI is poised to set new benchmarks for technological integration in oncology, ultimately aiming to redefine the standard of care for patients globally.
See full Onc.AI company page
